
Over recent years, there has been increased interest in the potential use of biomarkers in cancer.1–4 PD-L1 is one such biomarker.1
The aim of iD PD-L1 is to provide information for pathologists on PD-L1 expression testing, including: the pre-analytical stages, the practicalities of using, reading, interpreting and reporting PD-L1 assays, and training/quality control measures.